Recombinant Human MAP3K5 Protein, His (Fc)-Avi-tagged

• Cat.No.: MAP3K5-1359H
• Product Overview: Recombinant Human MAP3K5 with His (Fc)-Avi tag was expressed and purified

Specification

• Source: HEK293
• Species: Human
• Tag: His&Fc&Avi
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Purity: ≥85% by SDS-PAGE
• Stability: Stable for at least 6 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
• Storage: For long term storage, aliquot and store at -20 to -80 centigrade. Avoid repeated freezing and thawing cycles.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: MAP3K5 mitogen-activated protein kinase kinase kinase 5 [ Homo sapiens (human) ]
• Official Symbol: MAP3K5
• Synonyms: ASK1; MEKK5; MAPKKK5
• Gene ID: 4217
• mRNA Refseq: NM_005923.4
• Protein Refseq: NP_005914.1
• MIM: 602448
• UniProt ID: Q99683

Reviews

06/30/2020

The MAP3K5 protein has proven to be invaluable in protein electron microscopy structure analysis.

07/24/2018

Its ability to provide accurate and reliable results in this particular application makes it a preferred choice for researchers studying antigen-antibody interactions and immune responses.

12/01/2016

The MAP3K5 protein's sensitivity and specificity ensure precise measurements, contributing to the overall success of ELISA experiments.

Q&As

What other diseases or conditions involve MAP3K5?

MAP3K5 has been implicated in various diseases, including neurodegenerative disorders, cardiovascular diseases, and inflammatory conditions.

How is MAP3K5 protein implicated in cancer?

Aberrant regulation of MAP3K5 has been associated with cancer development, as it can influence cell survival and death pathways.

Can MAP3K5 be used as a biomarker for certain diseases?

MAP3K5 expression levels and activity may serve as biomarkers for specific diseases, providing valuable information for diagnosis and prognosis.

Are there any clinical applications of MAP3K5 in cancer treatment?

Research suggests that targeting MAP3K5 could have therapeutic implications in cancer treatment, potentially through the modulation of apoptosis in cancer cells.

Are there ongoing clinical trials involving MAP3K5 inhibitors?

Investigational studies and clinical trials are underway to explore the efficacy of MAP3K5 inhibitors in different disease contexts, including cancer.